

Chemotherapy: Bladder Cancer Valstar (valrubicin) J9357 Prior Authorization Request Medicare Part B Form

Instructions: * Indicates required information – Form may be returned if required information is not provided. Please fax this request to the appropriate fax number listed at the bottom of the page.

□ Standard Request– (72 Hours)				Urgent Request (standard time frame could place the member's life, health or ability in serious jeopardy)				
	Date Requested							
		r Clinic name:				/ Fax		
MEMBER INFORMATION								
*Name: *ID#: *						B:		
PRESCRIBER INFORMATION								
*Name:								
*Ado	lress:			*Fax:				
DISPENSING PROVIDER / ADMINISTRATION INFORMATION								
*Name: Phone:								
*Address: Fax:								
PROCEDURE / PRODUCT INFORMATION								
нс	PC Code	Name of Drug	Dos	e (Wt: kg Ht:)	Frequency	End Date if known	
□ Self-administered □ Provider-administered □ Home Infusion								
Chart notes attached. Other important information:								
Diagnosis: ICD10: Description:								
\square Provider attests the diagnosis provided is an FDA-Approved indication for this drug								
CLINICAL INFORMATION								
 New Start or Initial Request: (Clinical documentation required for all requests) Provider has reviewed the attached "Criteria for Approval" and attests the member meets ALL required PA criteria. If not, please provide clinical rationale for formulary exception: 								
□ Continuation Requests: (Clinical documentation required for all requests)								
Patient had an <u>adequate response</u> or <u>significant improvement</u> while on this medication. If not, please provide clinical rationale for continuing this medication:								
ACKNOWLEDGEMENT								
Request By (Signature Required):								



Prior Authorization Group - Oncology: Multiple Myeloma PA

Drug Name(s): VALSTAR VALRUBICIN

Criteria for approval of Prior Authorization Drug:

- 1. Prescribed for an approved FDA diagnosis (as listed below):
- 2. Prescribed by, or in consultation with an oncologist or other cancer specialist related to the diagnosis.
- 3. Drug is being used appropriately per CMS recognized compendia, authoritative medical literature, evidence-based guidelines and/or accepted standards of medical practice.
- 4. Member does not have any clinically relevant contraindications, or CMS/Plan exclusions, to the requested drug.
- If the member meets all these criteria, they may be approved by the Plan for the requested drug.
- Quantity limits and Tiering will be determined by the Plan.

Exclusion Criteria:

Cannot be prescribed for experimental or investigational use.

Prescriber Restrictions:

Oncologist or other cancer specialist

Coverage Duration:

New Start: Approval will be for 6 months Continuation: Approval will be for 12 months

FDA Indications:

Valstar

1. Cancer in situ of urinary bladder, BCG-refractory disease, in patients not candidates for immediate cystectomy

Off-Label Uses:

N/A

Age Restrictions:

The safety and effectiveness of valrubicin for intravesical installation have not been established in pediatric patients.

Other Clinical Considerations:

Criteria as per NCCN or other FDA-approved cancer related guidelines.

Resources:

https://www.micromedexsolutions.com/micromedex2/librarian/CS/2DEA8E/ND_PR/evidencexpert/ND_P/evidencexpert/DUPLICATIONSHIELDSYNC/FDBD23/ND_PG/evidencexpert/ND_B/evidencexpert/ND_AppProduct/evidencexpert/ND_T /evidencexpert/PFActionId/evidencexpert.GoToDashboard?docId=924828&contentSetId=100&title=Valrubicin&services Title=Valrubicin&brandName=Valstar&UserMdxSearchTerm=valstar&=null#